The route you choose determines where BPC-157 concentrates — and that determines what it heals. Oral and injectable BPC-157 are the same peptide but produce meaningfully different tissue distributions, onset profiles, and research applications.
Oral BPC-157 — The Gut Healer
Oral BPC-157 survives gastric acid — it was originally isolated from human gastric juice. When swallowed, it makes direct contact with the gut lining, activating EGR-1 and VEGFR2 locally. This makes it uniquely suited for IBD, leaky gut, SIBO, gastric ulcers, and post-antibiotic gut restoration. Typical research dose: 250–500 mcg/day, fasted.
Injectable BPC-157 — The Systemic Repairer
Subcutaneous or intramuscular injection bypasses the GI tract entirely, delivering BPC-157 directly into systemic circulation. This produces higher local concentrations at musculoskeletal injury sites — tendons, ligaments, muscle bellies — and faster CNS distribution for neuroprotective applications. Typical research dose: 200–400 mcg/day near the injury site.
Bioavailability & Route Comparison
Both routes activate the same EGR-1/VEGFR2/NO-cGMP signaling cascade, but at different tissue concentrations. Oral: high GI mucosal concentration, moderate systemic. Injection: high systemic and local musculoskeletal concentration, indirect GI effect. Dual-route protocols (oral + injection simultaneously) are used when both gut and systemic healing goals are present.